N/A N=113 Effects of Aromatherapy on Nausea Levels
Nausea, Postoperative
Primary: Patient Reported Nausea as Measured Visual Analog Scale (VAS) From 0-3 — 0; 0; 13; 13 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=1 ATRi Transition Rollover Study
Advanced Stage Solid Tumors
Primary: Number of Participants With Adverse Events (AEs) and Treatment Related AEs — 1; 0 Participants
N/A N=46 Crossover Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment
Cognition Disorders in Old Age · Mild Cognitive Impairment · Cognitive Decline
Primary: The Effect of Niagen vs PBO on Cognition as Measured by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). — 92.15; 91.04; 94.87; 95.17…
Early Phase 1 N=52 A Phase I Study to Evaluate LSALT Peptide
None - Study is to Determine Safety in Healthy Participants
Primary: Safety Evaluation — 3; 1; 6; 2 participants
N/A N=28 ACT to Reduce Morbidity and Mortality in Hematopoietic Stem Cell Transplant (HCT) Patients
Hematopoietic Steam Cell Transplantation (HCT)
Primary: Change in Physical Function, as Measured by 6 Minute Walk Test (6MWT) — 449; 468; 478 meters
N/A N=1,103 Measuring the Preferences of Patients With Type II Diabetes Using Best-worst Scaling and Discrete Choice Experiment
Type II Diabetes
Primary: Patient Medication Preference as Estimated by a Choice Model — 0.983; 0.362; 0.284; 0.261 utility of
N/A N=44 The Effect of Immediate Versus Delayed Debriefing on Basic Life Support Competence In Undergraduate Nursing Students.
BLS Competence · Debriefing
Primary: Basic Life Support Competence — 9.45; 10.04; 14.63; 14.54 score on a scale — p=<0.05
Phase 1 N=28 Bioequivalence Study of Test and Reference 120 mg Etoricoxib Film-coated Tablets in Healthy Volunteers
Bioequivalence · Healthy Subjects
Primary: Maximum Plasma Concentration (Cmax) — 1948.656; 1916.300 ng/mL
Phase 3 N=397 A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
Asthma
Primary: Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks — 0.56; 1.08 Exacerbation per participant per year — p=<0.001
N/A N=592 S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer
Bladder Cancer
Primary: 5-year Disease-free Survival (DFS) — 60; 56 percentage of participants — p=0.45
N/A N=380 Behavioral Economics and Self-Determination Theory to Change Diabetes Risk (BEST Change)
Pre Diabetes
Primary: Change in Hemoglobin A1c From Baseline to 6 Months — -0.05; -0.05; -0.04; -0.04 percentage of hemoglobin A1c — p=0.78
Phase 3 N=87 A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD
PTSD
Primary: Change From Baseline to Visit 16 in PCL-5 Total Score — -14.92 score on a scale
Phase 2 N=16 Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG
Alzheimer Disease
Primary: Number of TEAEs, Related TEAEs, SAEs, and Related SAEs — 6; 11; 4; 7 Participants
N/A N=10 Choline and Cardiometabolic Health
Cardiovascular Risk Factor
Primary: Change From Baseline in Insulin Sensitivity at 4 Weeks — 0.28; -0.29 Calculated Ratio - No units
N/A N=35 Prospective Elimination Of Distal Coronary Sinus-Left Atrial Connections for Atrial Fibrillation Ablation Trial
Atrial Fibrillation · Arrhythmias, Cardiac
Primary: Recurrence Rate of Atrial Arrhythmias — 8; 14; 7; 1 participants — p=0.047